Opinion
22-cv-04109-TSH
09-15-2023
HOTSPOT THERAPEUTICS, INC., Plaintiff, v. NURIX THERAPEUTICS, INC., Defendant.
PUBLIC REDACTED VERSION OF SEPTEMBER 15, 2023 DISCOVERY ORDER RE: DKT. NO. 116
THOMAS S. HIXSON UNITED STATES MAGISTRATE JUDGE
The Court held a hearing today concerning the parties' joint discovery letter brief at ECF No. 116. The Court now rules as follows:
Interrogatory No. 16. The Court Grants HotSpot's motion to compel. As to relevance, HotSpot argues that its right to use the [Redacted] outside of [Redacted]. Nurix disagrees, observing that [Redacted]. The Court is unwilling to decide what could be an important dispute over contract interpretation on a discovery motion and without evidence or testimony. Accordingly, the Court cannot say that identifying [Redacted] is irrelevant for discovery purposes. Nurix argues that it is burdensome but was unable to quantify that burden in a meaningful way.
Course of Conduct Evidence. The Court Grants HotSpot's motion to compel. HotSpot has demonstrated that Nurix's activities in [Redacted] are sufficiently relevant to the parties' course of conduct to justify discovery.
DEL-related Trade Secrets. As discussed at the hearing, the briefing on this issue was too truncated for the Court to properly understand the dispute. The Court Orders the parties to file a joint discovery letter brief on this issue no later than September 22, 2023.
Damages. The Court Grants HotSpot's motion to compel and Orders Nurix to amend its response to interrogatory 17 to include a computation of damages for each theory of damages it asserts.
IT IS SO ORDERED.